RxDoctor Payments Data

Huy Nguyen

Adult Medicine · Tampa, FLNPI 1255865622

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $661 and has fallen 61.7% since, to $253 in 2025.

$1,680in general payments, 2019–2025

Across 75 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$306
  • AbbVie$136
  • Pfizer$118
  • Johnson & Johnson$114
  • Intuity Medical Inc$91
  • Lilly USA, LLC$90
  • plus $825 from 23 others

What the payments were for

  • Food & beverage$1,680100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,680 in reported general payments places this provider in the 75th percentile of 195 adult medicine providers in Florida.

See all adult medicine providers in Florida

Medicare billing

Part B allowed, 2024
$40,463
Medicare patients
174
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$22,727
Repatha SureclickEvolocumab16$9,382
Atorvastatin Calcium164$1,207
Losartan Potassium67$947
Tamsulosin Hcl48$758
Ezetimibe25$680
Amlodipine Besylate77$620
Metoprolol Succinate32$548
Levothyroxine Sodium50$492
Gabapentin33$471
Simvastatin34$406
Rosuvastatin Calcium56$399
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide12$359
Pantoprazole Sodium32$335
Lisinopril63$300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$118$22,72724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 195 adult medicine providers in Florida.

Other adult medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →